Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato
California
94949
United States
Tel: 415-483-8800
Fax: 415-483-8810
Website: http://www.ultragenyx.com/careers/
Email: info@ultragenyx.com
About Ultragenyx Pharmaceutical Inc.
Founded in 2010, Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.
Where others turn away or take the road well traveled, we run towards the unknown and blaze new trails. We’re working hard to create treatments where none exist, giving new hope to patients with rare genetic diseases. Because you can only make a meaningful impact when your team has big ambitions. Join Ultragenyx and put your passion to work.
ultrafocused
Ultragenyx is dedicated to fostering a workplace environment that keeps our team inspired and provides the vision, resources and support they need to succeed. That includes maintaining a healthy, inclusive company culture where employees feel respected and valued. And providing opportunities for learning, personal growth, and career advancement. At Ultragenyx we push each other to perform at our very best, because we never lose sight of our mission – to make a difference in our patients’ lives.
308 articles with Ultragenyx Pharmaceutical Inc.
-
Ultragenyx to Host Conference Call for Second Quarter 2021 Financial Results and Corporate Update
7/27/2021
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel therapies for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Monday, August 2, 2021 at 5pm ET to discuss its financial results and corporate update for the quarter ended June 30, 2021.
-
Ultragenyx Receives Orphan Drug Designation from FDA and European Commission for UX053, an Investigational mRNA-therapy for the Treatment of Glycogen Storage Disease Type III
7/27/2021
Ultragenyx Pharmaceutical Inc. announced that the U.S. Food and Drug Administration and the European Commission have granted Orphan Drug Designation for UX053 for the treatment of Glycogen Storage Disease Type III, a metabolic disease that affects more than 10,000 patients in the developed world.
-
Several biotech and biopharmaceutical companies have announced new wins with the U.S. Food and Drug Administration (FDA), with these wins ranging from Investigational New Drug (IND) application approvals for cancer treatment candidates to Fast Track Designations for investigational agents aimed t...
-
BioSpace Movers & Shakers, July 2
7/2/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors
6/30/2021
Ultragenyx Pharmaceutical Inc. today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 29, 2021.
-
GeneTx and Ultragenyx Receive Approval from U.K. Regulatory Agency to Begin Clinical Study of GTX-102 for the Treatment of Angelman Syndrome
6/10/2021
GeneTx today announced that the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Clinical Trial Application (CTA) for the Phase 1/2 study of GTX-102 in pediatric patients with Angelman syndrome in the U.K.
-
Ultragenyx to Present at Goldman Sachs 42nd Annual Healthcare Conference
6/3/2021
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Goldman Sachs 42nd Annual Healthcare Conference
-
Ultragenyx to Present at Jefferies Virtual Healthcare Conference
5/26/2021
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Jefferies Virtual Healthcare Conference
-
Gene therapy is still very much cutting-edge with the potential to cure incurable genetic diseases. Here’s some recent news in the space.
-
GeneTx and Ultragenyx Receive Clearance from Health Canada to Begin Clinical Study of GTX-102 in Canada for the Treatment of Angelman Syndrome
5/19/2021
GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of intrathecally administered GTX-102, an investigational treatment for Angelman syndrome, today announced that they have received clearance from Health Canada to begin enrolling the Phase 1/2 study of GTX-102 in pediatric patients with Angelman syndrome in Canada.
-
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 18, 2021
5/18/2021
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, reported the grant of non-qualified stock options to purchase an aggregate of 4,677 shares of common stock of the company and 7,100 restricted stock units of the company’s common stock to a newly hired non-executive officer of the company.
-
Ultragenyx Announces Positive Multi-Year Durability Data from Ongoing Phase 1/2 Gene Therapy Studies and Data on HeLa 3.0 Manufacturing Platform at American Society of Gene & Cell Therapy 2021 Annual Meeting
5/14/2021
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today announced positive longer-term data from the Glycogen Storage Disease Type Ia (GSDIa) and Ornithine Transcarbamylase
-
The Rare Disease Company Coalition’s 10 founding members have brought 22 treatments to market and currently have more than 160 rare disease programs in the works.
-
Ultragenyx to Present at Bank of America Securities Healthcare Conference
5/10/2021
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Mardi Dier, the company's Chief Financial Officer and Camille Bedrosian, M.D., the company’s Chief Medical Officer, will present at the BofA Securities Healthcare Conference
-
Ultragenyx Reports First Quarter 2021 Financial Results and Corporate Update
5/4/2021
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, reported its financial results for the first quarter 2021 and reaffirmed its financial guidance for 2021.
-
Ultragenyx to Present at Truist Securities Life Sciences Summit
4/28/2021
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., will present at the 7th Annual Truist Securities Life Sciences Summit on Wednesday, May 5, 2021 at 1:00 PM ET.
-
Ultragenyx to Host Conference Call for First Quarter 2021 Financial Results and Corporate Update
4/28/2021
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel therapies for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, May 4, 2021 at 5pm ET to discuss its financial results and corporate update for the first quarter ended March 31, 2021.
-
Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy 2021 Virtual Annual Meeting
4/27/2021
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today announced that clinical, preclinical and manufacturing data from its investigational gene therapy programs will be presented at the American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting
-
Ultragenyx Completes Successful End-of-Phase 2 Meeting with FDA and Finalizes Phase 3 Study Design for DTX301 Ornithine Transcarbamylase (OTC) Gene Therapy ProgramPhase 3 Study on Track to Initiate in Second Half 2021
4/22/2021
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for the DTX301 ornithine transcarbamylase (OTC) deficiency gene therapy program.
-
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX053, an mRNA for the Treatment of Glycogen Storage Disease Type III
3/8/2021
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for UX053, an investigational mRNA therapy being evaluated for the treatment of Glycogen Storage Disease Type III (GSDIII).